

## Engineering Conferences International ECI Digital Archives

---

Cell Culture Engineering XV

Proceedings

---

Spring 5-10-2016

# Strategies for optimizing a cell culture platform to achieve high recombinant protein titer without impacting product quality

Natarajan Vijayasankaran  
*Genentech*, natarajv@gene.com

Robin Gruver  
*Genentech*

Steven Meier  
*Genentech*

Follow this and additional works at: [http://dc.engconfintl.org/cellculture\\_xv](http://dc.engconfintl.org/cellculture_xv)

 Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

### Recommended Citation

Natarajan Vijayasankaran, Robin Gruver, and Steven Meier, "Strategies for optimizing a cell culture platform to achieve high recombinant protein titer without impacting product quality" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016). [http://dc.engconfintl.org/cellculture\\_xv/91](http://dc.engconfintl.org/cellculture_xv/91)

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).

## **STRATEGIES FOR OPTIMIZING A CELL CULTURE PLATFORM TO ACHIEVE HIGH RECOMBINANT PROTEIN TITER WITHOUT IMPACTING PRODUCT QUALITY**

Natarajan Vijayasankaran, Late Stage Cell Culture, Genentech, Inc. South San Francisco, USA  
natarajv@gene.com

Robin Gruver, Late Stage Cell Culture, Genentech, Inc. South San Francisco, USA

Steven Meier, Late Stage Cell Culture, Genentech, Inc. South San Francisco, USA

**Key Words:** Fed-batch, acidic charge variants, product quality

Recent advances in cell line development and in the design of culture media have significantly increased both the volumetric and specific productivity of fed batch processes, which is our standard platform technology for synthesis of therapeutic proteins. Cell culture processes are generally simplified when needed as a robust platform technology to meet the imperatives of speedy timelines for early process development and ease of manufacturing. However, both culture media and feeding strategies need to be customized for specific cell lines when there is a need to achieve higher titer due to higher product demand. This presentation will focus on the specific changes that were made in order to enhance the platform cell culture process for achieving much higher titers. A case study will be used to demonstrate that changes made to feeding strategy, feed media and other process parameters have the potential to maximize productivity but also to alter the product quality profile. It is critical to ensure that these process changes do not adversely impact product quality. Strategies used to control the acidic charge variant profile, which was elevated in these enhanced cell culture processes, will be discussed.